Author/Authors :
Ma، نويسنده , , Brigette B.Y. and Lui، نويسنده , , Vivian W.Y. and Hui، نويسنده , , Connie W.C. and Lau، نويسنده , , Cecilia P.Y. and Wong، نويسنده , , Chi H. and Hui، نويسنده , , Edwin P. and Ng، نويسنده , , Margaret H.L. and Cheng، نويسنده , , Suk H. and Tsao، نويسنده , , Sai W. and Tsang، نويسنده , , Chi-Man and Cheung، نويسنده , , Crystal S.F. and Ho، نويسنده , , Kakiu and Chan، نويسنده , , Anthony T.C. Chan، نويسنده ,
Abstract :
The dual PI3K–mTOR inhibitor BEZ235 was evaluated in preclinical models of nasopharyngeal carcinoma (NPC). The IC50 value of BEZ235 for growth was in the nanomolar range in vitro, induce G1 cycle arrest and apoptosis, and inhibited AKT and mTOR signaling in most NPC cell lines. No synergistic effect was observed when BEZ235 was combined with chemotherapy. BEZ235 increased MAPK activation in vitro but not in vivo. A daily schedule was more effective than a weekly schedule on tumor growth and inhibition of downstream mTOR signaling in vivo. The activity of BEZ235 maybe independent of the PIK3CA amplification and mutation status.
